Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

DEXCOM INC Director's Dealing 2022

Jun 6, 2022

30198_dirs_2022-06-06_e04911d0-e720-4010-be02-5ef015e22110.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2022-06-06

Reporting Person: Sylvain Jereme M (EVP Chief Financial Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2022-06-06 Common Stock S 600 $301.57 Disposed 17408 Direct

Footnotes

F1: On June 4, 2021, Mr. Sylvain adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sylvain. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2: Included in this number are 13,583 unvested restricted stock units, 5,297 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,925 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 3,534 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 1,827 of which were granted on March 8, 2020 and shall vest through March 8, 2023.